Asset Details
Do you wish to reserve the book?
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV
Do you wish to request the book?
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV
2011
Overview
Chronic infection with hepatitis C virus (HCV) is a major public health problem, with nearly 170 million infected individuals worldwide. Current treatment for chronic infection is a combination of pegylated IFN-α2 and ribavirin (RBV); however, this treatment is effective in fewer than 50% of patients infected with HCV genotype 1 or 4. Recent studies identified the chemokine CXCL10 (also known as IP-10) as an important negative prognostic biomarker. Given that CXCL10 mediates chemoattraction of activated lymphocytes, it is counterintuitive that this chemokine correlates with therapeutic nonresponsiveness. Herein, we offer new insight into this paradox and provide evidence that CXCL10 in the plasma of patients chronically infected with HCV exists in an antagonist form, due to in situ amino-terminal truncation of the protein. We further demonstrated that dipeptidyl peptidase IV (DPP4; also known as CD26), possibly in combination with other proteases, mediates the generation of the antagonist form(s) of CXCL10. These data offer what we believe to be the first evidence for CXCL10 antagonism in human disease and identify a possible factor contributing to the inability of patients to clear HCV.
Publisher
American Society for Clinical Investigation
Subject
Antiviral Agents - therapeutic use
/ Chemokine CXCL10 - antagonists & inhibitors
/ Dipeptidyl Peptidase 4 - blood
/ Disease
/ Hepatitis C, Chronic - blood
/ Hepatitis C, Chronic - immunology
/ Hepatitis C, Chronic - therapy
/ Hepatitis C, Chronic - virology
/ Humans
/ Interferon-alpha - therapeutic use
/ Plasma
/ Polyethylene Glycols - therapeutic use
/ Proteins
